Could This Drug Become Vertex Pharmaceuticals' Next Blockbuster?

Vertex Pharmaceuticals (NASDAQ: VRTX) outperformed the broader market in the past decade. The drugmaker owes this performance to its monopoly in the market for medicines that treat the underlying causes of cystic fibrosis (CF), a rare genetic condition that harms a patient's internal organs.

However, as Vertex Pharmaceuticals has made headway into this patient population, some investors are increasingly worried about the company's post-CF plans. Fortunately, the biotech has several promising pipeline candidates, and it recently revealed some data from a clinical trial for one of them. Let's look closer at this potentially game-changing product Vertex Pharmaceuticals is currently working on.

Data by YCharts.